Navigation Links
CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG

Cell Therapeutics Inc (Seattle WA) has agreed to pay the US $10.5 millon to resolve allegations of the company's alleged illegal marketing// of the anti-cancer prescription drug Trisenox, the US Justice Department announced earlier this month.

According to the government's complaint, CTI promoted the drug for various uses that were unapproved by the US Food & Drug Administration (FDA).

The alleged "off-label" uses caused doctors to prescribe Trisenox to treat various forms of cancer for which the drug was neither approved by the FDA, nor proven to be either safe or effective. The government's suit alleged that because of the company's actions, physicians who prescribed Trisenox off-label unwittingly submitted false claims for reimbursement to the Medicare program from 2001-05. In 2005, CTI sold Trisenox to another company, and the drug's new owner halted CTI's misleading off-label promotion campaign.

"Cell Therapeutics essentially subverted a regulatory system designed to assure that patients receive only those drugs that have been proven to be effective for their illness," said Peter D. Keisler, Asst Attorney General for the Justice Dept's Civil Div.

Under the rules in effect at the time of the conduct in question, the complaint asserts that Medicare paid only for anti-cancer drugs when prescribed for FDA-approved uses, or uses that were determined to be medically accepted as published in certain specific pharmacological texts known collectively as the compendia. The government alleges that CTI knew that Trisenox was FDA-approved for only one type of cancer and was not listed as a medically accepted treatment in the compendia for any other condition. Nevertheless, the complaint states and claims that CTI falsely marketed the drug to doctors by suggesting that Trisenox was FDA-approved and listed as medically accepted in the compendia for other types of cancers.

"Cell Therapeutics enriched itself at taxpaye r expense by aggressively marketing this drug to doctors for use in treating certain types of cancers, even though the company knew that the drug had no proven medical benefit in the treatment of those cancers and had not been approved by the FDA for those uses," said Jeffrey C. Sullivan, US Attorney for the W District of WA.

In addition, the government's complaint alleges CTI used illegal kickbacks to induce physicians to prescribe Trisenox. Under sham "consulting agreements," physicians were paid $500-$1,000 to attend dinners or conferences on the off-label uses of Trisenox. These meetings were held at expensive resorts and restaurants. Doctors who wrote large numbers of prescriptions for Trisenox for off-label uses were asked to speak at various events for additional financial bonuses.

Source: BIOMEDICAL MARKET NEWSLETTER/M
'"/>




Related medicine news :

1. Mystery Surrounding Use Of Abortion Pill Yet To Be Resolved
2. Kenya Resolves to Fight Tuberculosis
3. Dispute in Findings about Radiation exposure
4. Radiographers Pay Parity Disputes Still Unresolved
5. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... San Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... million people suffering from acne, access to quality care can be limited while the ... skincare company that offers customized prescription acne care for every customer online, today released ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & Clients ... to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser ... $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a direct ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... be offered by the American Association of Integrative Medicine and available for application ... providers at the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, president ...
(Date:3/28/2017)... ... March 28, 2017 , ... The ... in Atlantic City March 13-16, was a busy spot this year. Liz Solovay ... discussed strategies for preventing outbreaks among camp communities during the upcoming 2017 camping ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... STRASBOURG, France and TEL AVIV, Israel ... opening a subsidiary in Israel . This new ... , will be mostly dedicated to research and development of novel ... Emosis Ltd will also, when relevant, locally support commercialization and sales ... ...
(Date:3/28/2017)...  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical ... other unmet medical needs, announced today two poster ... annual meeting.  The first poster to be presented ... ENMD-2076 in Combination with Anti-PD1 in Syngeneic Cancer ... presented on April 4 is entitled " Kinase ...
(Date:3/28/2017)... The global flow cytometry ... by 2025, according to a new study by Grand ... and cancer is expected to upsurge the demand for ... coming years. In addition, higher number of physicians is ... cell therapy, due to adverse effects caused by chemotherapy ...
Breaking Medicine Technology: